Innovent Biologics Secures FDA Fast Track for IBI3003 Trispecific Antibody in Multiple Myeloma
Innovent Biologics, Inc. (HKG: 1801) announced that the U.S. Food and Drug Administration (FDA) has...
Cancer
Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer
Daiichi Sankyo (TYO: 4568) announced that Raludotatug Deruxtecan (R‑DXd, DS‑6000a), a first‑in‑class CDH6‑targeted antibody‑drug conjugate (ADC),...
Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that SHR‑7877 has received National Medical Products...
China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial...
Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...
AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication
AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...
Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has...
Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...
BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform
Bristol‑Myers Squibb (BMS, NYSE: BMY) announced a collaboration with Microsoft to accelerate early detection of non‑small...
Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...
Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA)...
Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Grand Pharmaceutical Group Limited (HKG: 0512) announced it has filed TLX591-CDx (Illuccix, gallium Ga 68...
AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal
AbelZeta Pharma, Inc. (Sino‑US biotech) announced an agreement with AstraZeneca (AZ, NASDAQ: AZN) granting AZ the...
Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
Duality Biologics (HKG: 9606) announced that its ADAM9‑targeting ADC candidate DB‑1317 has received Investigational New...
Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China’s National Medical Products Administration (NMPA)...
Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors
Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649,...
WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development
WuXi Biologics (HKG: 2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) global exclusive...
ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development
ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM‑168, an...
Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange...
Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the U.S. Food and Drug Administration (FDA)...